Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations. IPX-203 (CD/LD extended-release capsules) In individuals who experience motor fluctuations; have 0.53 more hours of “Good On” time.
New extended release Levodopa formulation - Cure Parkinson's
New extended release Levodopa formulation
Written by
Buckholt
To view profiles and participate in discussions please or .
Read more about...
3 Replies
•
Is it available yet?
Phase 3 trial so not far off.
Thanks for sharing
Not what you're looking for?
You may also like...
Slow release cardopa/levodopa
neurologist changed my levodopa/cardopa to extended release 50/200 8 am,4pm,8pm and bed time...
Phase 3 Positive Topline Results for Tavapadon
Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for...
First Patient Dosed in Phase 3 Trial of Buntanetap for Early Parkinson's
for early-stage Parkinson’s disease, the company announced.
The Phase 3 clinical trial...
Levodopa =? Dyskinesia
Electroconvulsive Therapy Intervention for Parkinson’s Disease
example: High Dose Levodopa and Sleep
Zhittya announces \"Safe and Effective\" treatment for PD
